Open Access

ARTICLE

Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data

Lorenzo Gasperoni^1,*, Luna Del Bono², Alberto Farolfi³, Andrea Messori^4,5, Vera Damuzzo^5,6

1 Pharmaceutical Department, USL Toscana Centro, Prato, Italy
2 Department of Pharmacy, School of Specialization in Hospital Pharmacy, University of Pisa, Pisa, Italy
3 Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
4 HTA Unit, Regional Health Service, Firenze, Italy
5 Italian Society of Clinical Pharmacy and Therapeutics (SIFaCT), Torino, Italy
6 Hospital Pharmacy Department, Azienda Ulss 2 Marca Trevigiana, Treviso, Italy

* Corresponding Author: Lorenzo Gasperoni. Email:

Oncology Research 2026, 34(7), 14 https://doi.org/10.32604/or.2026.077700

Received 15 December 2025; Accepted 21 April 2026; Issue published 16 June 2026

Abstract

Background: Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are established maintenance treatments in ovarian cancer, but comparative efficacy across genetic profiles and relapse risk categories remains unclear. The aim of this study was to compare the efficacy of different PARPi as maintenance therapy in ovarian cancer across genetic profiles and relapse risk categories using reconstructed individual patient data (IPD) from randomized trials (RCTs). Methods: IPD were reconstructed using the IPDfromKM method from published Kaplan-Meier curves of RCTs stratified by clinical risk subgroup. Progression-free survival (PFS) was the primary endpoint. Three comparisons were performed: Breast Cancer gene (BRCA)+ high-risk, Homologous Recombination Deficiency (HRD)+/BRCAwt high-risk, and BRCA+ low-risk populations. Restricted Mean Survival Time (RMST) was calculated as a supplementary measure, with curves truncated at 66 months. Results: In the BRCA+ high-risk population, olaparib monotherapy (median PFS 41.2 months) and olaparib plus bevacizumab (median PFS 42.5 months) demonstrated the greatest PFS benefit, marginally outperforming niraparib (median PFS 31.2 months). RMST analysis showed a 14-month advantage for olaparib plus bevacizumab over bevacizumab alone. In the HRD+/BRCAwt high-risk population, olaparib plus bevacizumab and niraparib showed comparable efficacy, with no statistically significant inter-treatment difference. In the BRCA+ low-risk population, olaparib plus bevacizumab showed superior HR versus olaparib monotherapy, without reaching statistical significance. RMST analysis also indicated an advantage of 8.5 months for the combination, though this did not reach statistical significance. Conclusions: PARPi treatment benefit in ovarian cancer is meaningfully influenced by genetic profile and relapse risk, supporting biomarker-driven treatment selection in clinical practice.

---

Keywords

---

Supplementary Material

Supplementary Material File

---